Literature DB >> 14643652

Crystal structure of the human liver X receptor beta ligand-binding domain in complex with a synthetic agonist.

Stefan Hoerer1, Angela Schmid, Armin Heckel, Ralph M Budzinski, Herbert Nar.   

Abstract

LXRbeta belongs to the nuclear hormone receptor superfamily of ligand-activated transcription factors. Its natural ligands are supposed to be oxidised derivatives of cholesterol. Stimulation of LXRbeta by agonists activates a number of genes that are involved in the regulation of lipid metabolism and cholesterol efflux from cells. Therefore, LXRbeta may represent a novel therapeutic target for the treatment of dyslipidemia and atherosclerosis.Here, we report the X-ray crystal structure of the LXRbeta ligand-binding domain in complex with a synthetic agonist, T-0901317. This compound occupies the ligand-binding pocket of the receptor, forms numerous lipophilic contacts with the protein and one crucial hydrogen bond to His435 and stabilises the agonist conformation of the receptor ligand-binding domain. The recruitment of the AF2-region of the protein is not achieved via direct polar interactions of the ligand with protein side-chains of this helical segment, but rather via few hydrophobic contacts and probably more importantly via indirect effects involving the pre-orientation of side-chains that surround the ligand-binding pocket and form the interface to the AF2-helix. On the basis of these results we propose a binding mode and a mechanism of action for the putative natural ligands, oxidised derivatives of cholesterol.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14643652     DOI: 10.1016/j.jmb.2003.10.033

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  12 in total

1.  Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism.

Authors:  Yu Xue; Esther Chao; William J Zuercher; Timothy M Willson; Jon L Collins; Matthew R Redinbo
Journal:  Bioorg Med Chem       Date:  2006-12-20       Impact factor: 3.641

2.  Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR.

Authors:  Matthew D Krasowski; Ai Ni; Lee R Hagey; Sean Ekins
Journal:  Mol Cell Endocrinol       Date:  2010-07-06       Impact factor: 4.102

Review 3.  Nuclear receptors as drug targets for metabolic disease.

Authors:  Ira G Schulman
Journal:  Adv Drug Deliv Rev       Date:  2010-07-22       Impact factor: 15.470

4.  Identifying selective agonists targeting LXRβ from terpene compounds of alismatis rhizoma.

Authors:  Chuanjiong Lin; Jianzong Li; Chuanfang Wu; Jinku Bao
Journal:  J Mol Model       Date:  2021-02-22       Impact factor: 1.810

5.  LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly.

Authors:  Hugues de Boussac; Aurélien Jc Pommier; Julie Dufour; Amalia Trousson; Françoise Caira; David H Volle; Silvère Baron; Jean-Marc A Lobaccaro
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

6.  In silico identification of small molecules as novel LXR agonists for the treatment of cardiovascular disease and cancer.

Authors:  Xin Wang; Kaimin Lu; Hao Luo; Danfeng Liang; Xin Long; Yuan Yuan; Chuanfang Wu; Jinku Bao
Journal:  J Mol Model       Date:  2018-02-15       Impact factor: 1.810

7.  Intrinsic disorder in nuclear hormone receptors.

Authors:  Matthew D Krasowski; Erica J Reschly; Sean Ekins
Journal:  J Proteome Res       Date:  2008-07-24       Impact factor: 4.466

Review 8.  Liver X receptors at the intersection of lipid metabolism and atherogenesis.

Authors:  Stephen D Lee; Peter Tontonoz
Journal:  Atherosclerosis       Date:  2015-07-02       Impact factor: 5.162

9.  Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate.

Authors:  Reyna K V Lim; Shan Yu; Bo Cheng; Sijia Li; Nam-Jung Kim; Yu Cao; Victor Chi; Ji Young Kim; Arnab K Chatterjee; Peter G Schultz; Matthew S Tremblay; Stephanie A Kazane
Journal:  Bioconjug Chem       Date:  2015-05-20       Impact factor: 4.774

10.  Ligand specificity and evolution of liver X receptors.

Authors:  Erica J Reschly; Ni Ai; William J Welsh; Sean Ekins; Lee R Hagey; Matthew D Krasowski
Journal:  J Steroid Biochem Mol Biol       Date:  2008-03-10       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.